You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,420,828


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,420,828
Title:Inhibitors
Abstract: Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
Inventor(s): Heiser; Ulrich (Halle/Saale, DE), Gaertner; Ulf-Torsten (Halle/Saale, DE), Demuth; Hans-Ulrich (Halle/Saale, DE)
Assignee: Probiodrug AG (Halle/Salle, DE)
Application Number:13/547,501
Patent Claims:1. A compound of formula (I): ##STR00049## or a pharmaceutically acceptable salt thereof, including all tautomers and stereoisomers thereof wherein: R.sup.1 represents -aryl, in which aforesaid aryl may optionally be substituted by one or more groups selected from nitro, halogen, cyano, and hydroxyl; R.sup.2 represents C.sub.1-6alkyl or C.sub.1-6haloalkyl; and R.sup.3 represents C.sub.1-6alkyl or C.sub.1-6haloalkyl.

2. A compound according to claim 1, wherein R.sup.1 represents phenyl optionally substituted by one or more groups selected from nitro, halogen, cyano, and hydroxyl.

3. A compound according to claim 1, wherein R.sup.1 represents phenyl optionally substituted by one or more halogen groups.

4. A compound according to claim 3, wherein R.sup.1 represents 2,3-difluorophenyl.

5. A compound according to claim 3, wherein R.sup.2 represents C.sub.1-6haloalkyl.

6. A compound according to claim 5, wherein R.sup.2 represents trifluoromethyl.

7. A compound according to claim 3, wherein R.sup.2 represents C.sub.1-6alkyl.

8. A compound according to claim 7, wherein R.sup.2 represents methyl, ethyl, propyl or isopropyl.

9. A compound according to claim 8, wherein R.sup.2 represents methyl.

10. A compound according to claim 3, wherein R.sup.3 represents C.sub.1-6haloalkyl.

11. A compound according to claim 10, wherein R.sup.3 represents 2,2,2-trifluoromethyl or 2,2,3,3-tetrafluoropropyl.

12. A compound according to claim 3, wherein R.sup.3 represents C.sub.1-6alkyl.

13. A compound according to claim 12, wherein R.sup.3 represents methyl or ethyl.

14. A compound or a pharmaceutically acceptable salt thereof, including all tautomers and stereoisomers, selected from the group consisting of: ##STR00050## ##STR00051## ##STR00052## ##STR00053##

15. A compound according to claim 1, which is 1-(1H-benzo[d]imidazol-6-yl)-5-(2,3-difluorophenyl)-3-methoxy-4-methyl-1H- -pyrrol-2(5H)-one or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1, which is (R)-1-(1H-benzo[d]imidazol-6-yl)-5-(2,3-difluorophenyl)-3-methoxy-4-methy- l-1H-pyrrol-2(5H)-one or a pharmaceutically acceptable salt thereof.

17. A compound according to claim 1, which is (S)-1-(1H-benzo[d]imidazol-6-yl)-5-(2,3-difluorophenyl)-3-methoxy-4-methy- l-1H-pyrrol-2(5H)-one or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound according to claim 1, optionally in combination with one or more therapeutically acceptable diluents or carriers.

19. The pharmaceutical composition according to claim 18, wherein the compound is selected from the group consisting of: ##STR00054## ##STR00055## ##STR00056## ##STR00057##

20. The pharmaceutical composition of claim 18, which comprises additionally at least one compound, selected from the group consisting of neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.

21. The pharmaceutical composition of claim 18, which comprises additionally at least one compound, selected from the group consisting of PEP-inhibitors, LiCI, inhibitors of inhibitors of DP IV or DP IV-like enzymes, acetylcholinesterase (ACE) inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases, inhibitors of neutral endopeptidase, inhibitors of Phosphodiesterase-4 (PDE-4), TNFalpha inhibitors, muscarinic M1 receptor antagonists, NMDA receptor antagonists, sigma-1 receptor inhibitors, histamine H3 antagonists, immunomodulatory agents, immunosuppressive agents or an agent selected from the group consisting of antegren (natalizumab), Neurelan (fampridine-SR), campath (alemtuzumab), IR 208, NBI 5788/MSP 771 (tiplimotide), paclitaxel, Anergix.MS (AG 284), SH636, Differin (CD 271, adapalene), BAY 361677 (interleukin-4), matrix-metalloproteinase-inhibitors, interferon-tau (trophoblastin) and SAIK-MS.

22. A method of treatment of: (i) a disease selected from the group consisting of mild cognitive impairment, Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, neurodegeneration in Down Syndrome and Huntington's disease; or (ii) a disease selected from the group consisting of rheumatoid arthritis, atherosclerosis, pancreatitis and restenosis; the method comprising administering to a subject an effective amount of a compound according to claim 1, optionally in combination with one or more therapeutically acceptable diluents or carriers.

23. The method of treatment according to claim 22, wherein the disease is selected from the group consisting of mild cognitive impairment, Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, neurodegeneration in Down Syndrome and Huntington's disease.

24. The method of treatment according to claim 22, wherein the disease is selected from the group consisting of rheumatoid arthritis, atherosclerosis, pancreatitis and restenosis.

25. A process for preparation of a compound of formula (I) according to claim 1, which comprises: (a) preparing a compound of formula (I) from a compound of formula (II) ##STR00058## wherein R.sup.1 and R.sup.2 are as defined in claim 1; (b) interconversion of compounds of formula (I); and/or (c) deprotecting a compound of formula (I) which is protected.

Details for Patent 8,420,828

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Jubilant Hollisterstier Llc N/A positive skin test control-histamine Injection 103891 03/13/1924 ⤷  Try a Trial 2030-03-10
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2030-03-10
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 11/14/2014 ⤷  Try a Trial 2030-03-10
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 10/12/2004 ⤷  Try a Trial 2030-03-10
Biogen Inc. TYSABRI natalizumab Injection 125104 11/23/2004 ⤷  Try a Trial 2030-03-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.